New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases.

data sharing diagnostic odyssey genomics omic approaches rare disease diagnosis rare genetic diseases

Journal

Annual review of genomics and human genetics
ISSN: 1545-293X
Titre abrégé: Annu Rev Genomics Hum Genet
Pays: United States
ID NLM: 100911346

Informations de publication

Date de publication:
31 08 2020
Historique:
pubmed: 15 4 2020
medline: 25 6 2021
entrez: 15 4 2020
Statut: ppublish

Résumé

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis. The current diagnostic paradigm is not well designed for RGDs, especially for patients who remain undiagnosed after the initial set of investigations, and thus requires an expansion of approaches in the clinic. Leveraging opportunities to participate in research programs that utilize new technologies to understand RGDs is an important path forward for patients seeking a diagnosis. Given recent advancements in such technologies and international initiatives, the prospect of identifying a molecular diagnosis for all patients with RGDs has never been so attainable, but achieving this goal will require global cooperation at an unprecedented scale.

Identifiants

pubmed: 32283948
doi: 10.1146/annurev-genom-083118-015345
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

351-372

Subventions

Organisme : CIHR
ID : FDN-154279
Pays : Canada

Auteurs

Taila Hartley (T)

CHEO Research Institute, University of Ottawa, Ottawa, Ontario K1H 8L1, Canada; email: thartley@cheo.on.ca, glemire@cheo.on.ca, kkernohan@cheo.on.ca, hhowley@cheo.on.ca, kboycott@cheo.on.ca.

Gabrielle Lemire (G)

CHEO Research Institute, University of Ottawa, Ottawa, Ontario K1H 8L1, Canada; email: thartley@cheo.on.ca, glemire@cheo.on.ca, kkernohan@cheo.on.ca, hhowley@cheo.on.ca, kboycott@cheo.on.ca.
Department of Genetics, CHEO, Ottawa, Ontario K1H 8L1, Canada.

Kristin D Kernohan (KD)

CHEO Research Institute, University of Ottawa, Ottawa, Ontario K1H 8L1, Canada; email: thartley@cheo.on.ca, glemire@cheo.on.ca, kkernohan@cheo.on.ca, hhowley@cheo.on.ca, kboycott@cheo.on.ca.
Newborn Screening Ontario, CHEO, Ottawa, Ontario K1H 9M8, Canada.

Heather E Howley (HE)

CHEO Research Institute, University of Ottawa, Ottawa, Ontario K1H 8L1, Canada; email: thartley@cheo.on.ca, glemire@cheo.on.ca, kkernohan@cheo.on.ca, hhowley@cheo.on.ca, kboycott@cheo.on.ca.

David R Adams (DR)

Office of the Clinical Director, National Human Genome Research Institute and Undiagnosed Diseases Program, National Institutes of Health, Bethesda, Maryland 20892, USA; email: david.adams@nih.gov.

Kym M Boycott (KM)

CHEO Research Institute, University of Ottawa, Ottawa, Ontario K1H 8L1, Canada; email: thartley@cheo.on.ca, glemire@cheo.on.ca, kkernohan@cheo.on.ca, hhowley@cheo.on.ca, kboycott@cheo.on.ca.
Department of Genetics, CHEO, Ottawa, Ontario K1H 8L1, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH